These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10764968

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
    Portnoy YA, Vostrov SN, Lubenko IY, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antimicrobial activities of tosufloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella branhamella catarrhalis isolated from otolaryngological infectious diseases.
    Suzuki K, Fujisawa T, Nakashima M, Hamasaki R.
    J Infect Chemother; 2005 Oct; 11(5):253-5. PubMed ID: 16258823
    [Abstract] [Full Text] [Related]

  • 27. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
    Kitzis MD, Goldstein FW, Miegi M, Acar JF.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
    [Abstract] [Full Text] [Related]

  • 28. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
    Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF.
    J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
    [Abstract] [Full Text] [Related]

  • 29. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F, Carnegy F, Willcock J, Amyes S.
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA, Ehrhardt AF, Jones RN.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM, Suter M, Borsos S.
    J Antimicrob Chemother; 1999 Mar 17; 43 Suppl A():25-30. PubMed ID: 10225568
    [Abstract] [Full Text] [Related]

  • 34. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.
    Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K.
    Chemotherapy; 2004 Dec 17; 50(6):265-75. PubMed ID: 15608441
    [Abstract] [Full Text] [Related]

  • 35. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF, Brown NP, Thornsberry C, Jones ME.
    Postgrad Med; 2008 Sep 17; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [Abstract] [Full Text] [Related]

  • 36. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).
    DiPersio JR, Jones RN, Barrett T, Doern GV, Pfaller MA.
    Diagn Microbiol Infect Dis; 1998 Oct 17; 32(2):131-5. PubMed ID: 9823538
    [Abstract] [Full Text] [Related]

  • 37. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
    Gales AC, Gordon KA, Wilke WW, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jan 17; 36(1):61-4. PubMed ID: 10744370
    [Abstract] [Full Text] [Related]

  • 38. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
    Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R, BSAC Working Parties on Resistance Surveillance.
    J Antimicrob Chemother; 2008 Nov 17; 62 Suppl 2():ii97-103. PubMed ID: 18819984
    [Abstract] [Full Text] [Related]

  • 39. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
    Fedler KA, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Dec 17; 56(4):427-36. PubMed ID: 16938419
    [Abstract] [Full Text] [Related]

  • 40. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Ishihara S, Kawada Y.
    J Antimicrob Chemother; 1997 Oct 17; 40(4):543-9. PubMed ID: 9372424
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.